Mingjie An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mingjie An has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Changhao Chen
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
33 shared publications - Hanhao Zheng
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
32 shared publications - Yan Lin
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
32 shared publications - Yao Kong
Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China
32 shared publications - Jiancheng Chen
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
26 shared publications - Mingrui Pang
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
26 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (2) , 856-867
Molecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise
Lymphangiogenesis is considered the rate-limiting step for tumor lymph node (LN) metastasis by sprouting the new lymphatic network from preexisting lymphatic vessels to favor the invasion and entry of cancer cells into the lymphatic system. Over the past decade, numerous studies have investigated the cellular roles and molecular mechanisms of lymphangiogenesis in cancers, and corresponding molecular control strategies targeting lymphangiogenesis to treat LN metastatic cancers have been developed. Nevertheless, due to the crucial role of lymphatic vessels in the infiltration of immune cells and immune activation in cancers, there have been several diverse findings regarding the biological roles and strategies of targeting tumor lymphangiogenesis as cancer immunotherapy has emerged and rapidly developed. Herein, we summarize the progress in characterizing the molecular mechanisms and therapeutic strategies involved in tumor lymphangiogenesis and highlight the potential of targeting lymphangiogenesis in combination with immunotherapy for the treatment of cancer, providing opportunities to improve the efficacy of targeting lymphangiogenesis to prevent cancer metastasis.
- 1 March 2026
- Published by KEAI Publishing in Fundamental Research
- Vol. 6 (2) , 856-867
Open AccessMolecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise
Lymphangiogenesis is considered the rate-limiting step for tumor lymph node (LN) metastasis by sprouting the new lymphatic network from preexisting lymphatic vessels to favor the invasion and entry of cancer cells into the lymphatic system. Over the past decade, numerous studies have investigated the cellular roles and molecular mechanisms of lymphangiogenesis in cancers, and corresponding molecular control strategies targeting lymphangiogenesis to treat LN metastatic cancers have been developed. Nevertheless, due to the crucial role of lymphatic vessels in the infiltration of immune cells and immune activation in cancers, there have been several diverse findings regarding the biological roles and strategies of targeting tumor lymphangiogenesis as cancer immunotherapy has emerged and rapidly developed. Herein, we summarize the progress in characterizing the molecular mechanisms and therapeutic strategies involved in tumor lymphangiogenesis and highlight the potential of targeting lymphangiogenesis in combination with immunotherapy for the treatment of cancer, providing opportunities to improve the efficacy of targeting lymphangiogenesis to prevent cancer metastasis.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Circular RNAs (circRNAs) contribute to cancer stemness, proliferation, and metastasis. The biogenesis of circRNAs can be impacted by the genetic landscape of tumors. Herein, we identified a novel circRNA, circARFGEF2 (hsa_circ_0060665), which was upregulated in KRASG12D pancreatic ductal adenocarcinoma (PDAC) and positively associated with KRASG12D PDAC lymph node (LN) metastasis. CircARFGEF2 overexpression significantly facilitated KRASG12D PDAC LN metastasis in vitro and in vivo. Mechanistically, circARFGEF2 biogenesis in KRASG12D PDAC was significantly activated by the alternative splicing factor QKI-5, which recruited U2AF35 to facilitate spliceosome assembly. QKI-5 bound the QKI binding motifs and neighboring reverse complement sequence in intron 3 and 6 of ARFGEF2 pre-mRNA to facilitate circARFGEF2 biogenesis. CircARFGEF2 sponged miR-1205 and promoted the activation of JAK2, which phosphorylated STAT3 to trigger KRASG12D PDAC lymphangiogenesis and LN metastasis. Importantly, circARFGEF2 silencing significantly inhibited LN metastasis in the KrasG12D/+Trp53R172H/+Pdx-1-Cre (KPC) mouse PDAC model. These findings provide insight into the mechanism and metastasis-promoting function of mutant KRAS-mediated circRNA biogenesis.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Circular RNAs (circRNAs) contribute to cancer stemness, proliferation, and metastasis. The biogenesis of circRNAs can be impacted by the genetic landscape of tumors. Herein, we identified a novel circRNA, circARFGEF2 (hsa_circ_0060665), which was upregulated in KRASG12D pancreatic ductal adenocarcinoma (PDAC) and positively associated with KRASG12D PDAC lymph node (LN) metastasis. CircARFGEF2 overexpression significantly facilitated KRASG12D PDAC LN metastasis in vitro and in vivo. Mechanistically, circARFGEF2 biogenesis in KRASG12D PDAC was significantly activated by the alternative splicing factor QKI-5, which recruited U2AF35 to facilitate spliceosome assembly. QKI-5 bound the QKI binding motifs and neighboring reverse complement sequence in intron 3 and 6 of ARFGEF2 pre-mRNA to facilitate circARFGEF2 biogenesis. CircARFGEF2 sponged miR-1205 and promoted the activation of JAK2, which phosphorylated STAT3 to trigger KRASG12D PDAC lymphangiogenesis and LN metastasis. Importantly, circARFGEF2 silencing significantly inhibited LN metastasis in the KrasG12D/+Trp53R172H/+Pdx-1-Cre (KPC) mouse PDAC model. These findings provide insight into the mechanism and metastasis-promoting function of mutant KRAS-mediated circRNA biogenesis.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma
Figure S1-S10, Table S1-S5 and Supplementary methods
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Data from SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer
Aberrant gene expression is a prominent feature of metastatic cancer. Translational initiation is a vital step in fine-tuning gene expression. Thus, exploring translation initiation regulators may identify therapeutic targets for preventing and treating metastasis. Herein, we identified that DHCR24 was overexpressed in lymph node (LN) metastatic bladder cancer and correlated with poor prognosis of patients. DHCR24 promoted lymphangiogenesis and LN metastasis of bladder cancer in vitro and in vivo. Mechanistically, DHCR24 mediated and recognized the SUMO2 modification at lysine 108 of hnRNPA2B1 to foster TBK1 mRNA circularization and eIF4F initiation complex assembly by enhancing hnRNPA2B1–eIF4G1 interaction. Moreover, DHCR24 directly anchored to TBK1 mRNA 3′-untranslated region to increase its stability, thus forming a feed forward loop to elevate TBK1 expression. TBK1 activated PI3K/Akt signaling to promote VEGFC secretion, resulting in lymphangiogenesis and LN metastasis. DHCR24 silencing significantly impeded bladder cancer lymphangiogenesis and lymphatic metastasis in a patient-derived xenograft model. Collectively, these findings elucidate DHCR24-mediated translation machinery that promotes lymphatic metastasis of bladder cancer and supports the potential application of DHCR24-targeted therapy for LN-metastatic bladder cancer.Significance:DHCR24 is a SUMOylation regulator that controls translation initiation complex assembly and orchestrates TBK1 mRNA circularization to activate Akt/VEGFC signaling, which stimulates lymphangiogenesis and promotes lymph node metastasis in bladder cancer.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer
Aberrant gene expression is a prominent feature of metastatic cancer. Translational initiation is a vital step in fine-tuning gene expression. Thus, exploring translation initiation regulators may identify therapeutic targets for preventing and treating metastasis. Herein, we identified that DHCR24 was overexpressed in lymph node (LN) metastatic bladder cancer and correlated with poor prognosis of patients. DHCR24 promoted lymphangiogenesis and LN metastasis of bladder cancer in vitro and in vivo. Mechanistically, DHCR24 mediated and recognized the SUMO2 modification at lysine 108 of hnRNPA2B1 to foster TBK1 mRNA circularization and eIF4F initiation complex assembly by enhancing hnRNPA2B1–eIF4G1 interaction. Moreover, DHCR24 directly anchored to TBK1 mRNA 3′-untranslated region to increase its stability, thus forming a feed forward loop to elevate TBK1 expression. TBK1 activated PI3K/Akt signaling to promote VEGFC secretion, resulting in lymphangiogenesis and LN metastasis. DHCR24 silencing significantly impeded bladder cancer lymphangiogenesis and lymphatic metastasis in a patient-derived xenograft model. Collectively, these findings elucidate DHCR24-mediated translation machinery that promotes lymphatic metastasis of bladder cancer and supports the potential application of DHCR24-targeted therapy for LN-metastatic bladder cancer.Significance:DHCR24 is a SUMOylation regulator that controls translation initiation complex assembly and orchestrates TBK1 mRNA circularization to activate Akt/VEGFC signaling, which stimulates lymphangiogenesis and promotes lymph node metastasis in bladder cancer.